乳腺癌新辅助化疗临床研究进展

被引：7

作者：

李秀清

周文斌

潘红

刘晓安

机构：

[1] 南京医科大学附属医院乳腺外科

来源：

江苏医药 | 2016年 / 42卷 / 09期

关键词：

D O I：

10.19460/j.cnki.0253-3685.2016.09.021

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

新辅助化疗是乳腺癌患者全身治疗的重要组成部分,新辅助化疗可减轻肿瘤负荷、降低临床分期、提高保乳率、了解化疗药物敏感性。本文综述乳腺癌新辅助化疗的理论基础、适用范围、常用方案、其与保乳、前哨淋巴结活检术的关系及其疗效预测因子等的研究进展。

引用

页码：1053 / 1055

页数：3

共 8 条

[1]

Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients.[J].Richard J. Bleicher;Karen Ruth;Elin R. Sigurdson;John M. Daly;Marcia Boraas;Penny R. Anderson;Brian L. Egleston.Cancer.2016, 1

[2]

Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance) [J].

Boughey, Judy C. ;

Ballman, Karla V. ;

Hunt, Kelly K. ;

McCall, Linda M. ;

Mittendorf, Elizabeth A. ;

Ahrendt, Gretchen M. ;

Wilke, Lee G. ;

Le-Petross, Huong T. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) :3386-+

[3]

Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study [J].

Dodiya, Hardik G. ;

Brahmbhatt, Alay P. ;

Khatri, Priyanka K. ;

Kaushal, Ashish M. ;

Vijay, D. G. .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (03) :612-616

[4]

A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC 100 ) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).[J].C. Delbaldo;D. Serin;M. Mousseau;S. Greget;B. Audhuy;F. Priou;J.F. Berdah;E. Teissier;P. Laplaige;L. Zelek;E. Quinaux;M. Buyse;P. Piedbois.European Journal of Cancer.2014, 1

[5]

Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor–positive Breast Cancer [J].

Sheng Chen ;

Can-Ming Chen ;

Ke-Da Yu ;

Ruo-Ji Zhou ;

Zhi-Ming Shao .

Annals of Surgical Oncology, 2012, 19 :3002-3011

[6]

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J].

Gianni, Luca ;

Pienkowski, Tadeusz ;

Im, Young-Hyuck ;

Roman, Laslo ;

Tseng, Ling-Ming ;

Liu, Mei-Ching ;

Lluch, Ana ;

Staroslawska, Elzbieta ;

de la Haba-Rodriguez, Juan ;

Im, Seock-Ah ;

Pedrini, Jose Luiz ;

Poirier, Brigitte ;

Morandi, Paolo ;

Semiglazov, Vladimir ;

Srimuninnimit, Vichien ;

Bianchi, Giulia ;

Szado, Tania ;

Ratnayake, Jayantha ;

Ross, Graham ;

Valagussa, Pinuccia .

LANCET ONCOLOGY, 2012, 13 (01) :25-32

[7]

HER2-overexpressing breast cancer: time for the cure with less chemotherapy? [J].

Loi, Sherene ;

de Azambuja, Evandro ;

Pugliano, Lina ;

Sotiriou, Christos ;

Piccart, Martine J. .

CURRENT OPINION IN ONCOLOGY, 2011, 23 (06) :547-558

[8]

MRI三维评价乳腺癌新辅助化疗后残余肿瘤范围的准确性.[J].杨涛;张朝蓬;刘广;穆殿斌;孙翔宇;陈兆秋;刘雁冰;王春建;孙晓;王永胜;.中华外科杂志.2015, 04

← 1 →